Study of the effect of addition of iguratimod (IGU) on clinical remission rate after biologic disease modified anti-rheumatic drugs (bDMARDs) discontinuation in patients with rheumatoid arthritis(RA) .
Not Applicable
- Conditions
- rheumatoid arthritis
- Registration Number
- JPRN-UMIN000044255
- Lead Sponsor
- Osaka Medical and Pharmaceutical University Department of Internal Medicine (IV)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with IGU contraindications, such as during warfarin potassium.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method